US Pharm. 2012;36(2):40.
Amerigen Pharmaceuticals Limited (East Brunswick, NJ) and VIWA Pharmaceutical Company Limited (Hangzhou, China) jointly announced the signing of a memorandum of understanding setting out their intention to establish a joint venture to develop and register a range of branded generic medicines for sale in China. It is anticipated that the products, once approved, would be manufactured at Amerigen’s SFDA (China’s State Food and Drug Administration) and United States FDA approved finished dose plant in Suzhou, China, with marketing and sales undertaken either by a Chinese affiliate of VIWA or a third party.
Jonathan Embleton, Amerigen’s chief business officer, said, “We look forward to working with VIWA to bring some first time and technically sophisticated generic products to Chinese patients at more affordable prices, without compromising on quality.”
